Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Seiichiro Hojo
Observed names:
S Hojo,
S. Hojo,
Seiichiro HOJO
Institution:
Eisai (Japan)
Observed institutions:
Toray (United States),
Toray Industries, Inc. (Japan),
Eisai (Japan)
OpenAlex ID:
A5001074370
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses: The Journal of Clinical Pharmacology
2017
·
Toshiyuki Tamai
, Seiichi Hayato
, et al.
·
The Journal of Clinical Pharmacology
·
110
PDF
Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in J apanese adult patients with atopic dermatitis: Results of a randomized, vehicle‐controlled, multicenter clinical trial
2014
·
Masutaka Furue
, Yasumi Kitahara
, et al.
·
The Journal of Dermatology
·
80
Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis
2017
·
Yoshiya Tanaka
, Tsutomu Takeuchi
, et al.
·
Modern Rheumatology
·
62
Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan
2021
·
Koji Izutsu
, Kiyoshi Ando
, et al.
·
Cancer Science
·
59
PDF
Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle‐controlled exploratory trial
2015
·
Osamu Nemoto
, Nobukazu Hayashi
, et al.
·
The Journal of Dermatology
·
49
Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study
2016
·
Fuminori Ohba
, Shunji Matsuki
, et al.
·
Journal of Dermatological Treatment
·
48
Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study
2017
·
Yoshikazu Kinoshita
, Mototsugu Kato
, et al.
·
Journal of Gastroenterology
·
34
PDF
Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study
2020
·
Yoshiya Tanaka
, Tsutomu Takeuchi
, et al.
·
Arthritis & Rheumatology
·
33
PDF
A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs
2021
·
Yoshiya Tanaka
, Tsutomu Takeuchi
, et al.
·
Modern Rheumatology
·
26
Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease
2021
·
Katsuyoshi Matsuoka
, Makoto Naganuma
, et al.
·
Journal of Gastroenterology and Hepatology
·
24
Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis
2015
·
Fuminori Ohba
, Maiko Nomoto
, et al.
·
Journal of Dermatological Treatment
·
23
First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers
2022
·
Naoto Yamakawa
, Fumitoshi Tago
, et al.
·
Clinical Pharmacology in Drug Development
·
21
Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes
2011
·
Seiichi Hayato
, Setsuo Hasegawa
, et al.
·
European Journal of Clinical Pharmacology
·
17
Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate
2023
·
Yoshiya Tanaka
, Tsutomu Takeuchi
, et al.
·
Modern Rheumatology
·
10
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study
2024
·
Koji Izutsu
, Kiyoshi Ando
, et al.
·
International Journal of Hematology
·
7
PDF
A placebo-controlled Phase 2 trial of E6011, anti-human fractalkine monoclonal antibody, in primary biliary cholangitis
2025
·
Atsushi Tanaka
, Masanori Abe
, et al.
·
Journal of Translational Autoimmunity
·
5
Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis
2018
·
Yasumi Kitahara
, Seiichiro Hojo
, et al.
·
Journal of Dermatological Treatment
·
5
PDF
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs
2023
·
Yoshiya Tanaka
, Tsutomu Takeuchi
, et al.
·
Modern Rheumatology
·
4
Op0223 Efficacy and Safety of E6011, an Anti-fractalkine Monoclonal Antibody, in Mtx-ir Patients With Rheumatoid Arthritis
2019
·
Yoshiya Tanaka
, Tsutomu Takeuchi
, et al.
·
Annals of the Rheumatic Diseases
·
4
PDF
DOP056 Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn’s disease who had lost response to anti-TNFα agents: A multicentre, open-label, Phase 1/2 study
2018
·
K Matsuoka
, M Naganuma
, et al.
·
Journal of Crohn s and Colitis
·
4
Sat0126 a Phase 2 Study of E6011, an Anti-fractalkine Monoclonal Antibody, in Patients With Rheumatoid Arthritis Inadequately Responding to Biologics
2019
·
Yoshiya Tanaka
, Tsutomu Takeuchi
, et al.
·
Annals of the Rheumatic Diseases
·
3
PDF
Mo1890 Safety, Tolerability and Efficacy of E6011, Anti-Human Fractalkine Monoclonal Antibody, in the First-in-Patient Study for Crohn's Disease
2016
·
Katsuyoshi Matsuoka
, Makoto Naganuma
, et al.
·
Gastroenterology
·
3
Histological characteristics of primary biliary cholangitis in patients with incomplete responses to ursodeoxycholic acid
2025
·
Kenichi Harada
, Yuko Kakuda
, et al.
·
Human Pathology
·
2
FRI0236 Safety, Pharmacokinetics and Efficacy of E6011, An Anti-Fractalkine Monoclonal Antibody, in A First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
2016
·
Y. Tanaka
, T. Takeuchi
, et al.
·
Annals of the Rheumatic Diseases
·
2
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
2020
·
Yoshiya Tanaka
, Tsutomu Takeuchi
, et al.
·
SSRN Electronic Journal
·
1
Show more works
View as search
Works count:
31
Citation count:
638
H-index:
13
I10-index:
14
Year
Topic
Type